Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB1U8V)

Drug Name
CYCLORPHAN Drug Info
Synonyms
17-(Cyclopropylmethyl)morphinan-3-ol; 4163-15-9; UNII-U6Z73N36V0; EINECS 224-007-5; CHEMBL49269; (-)-3-Hydroxy-N-cyclopropylmethylmorphinan; U6Z73N36V0; Morphinan, (-)-3-hydroxy-N-cyclopropylmethyl-; Morphinan-3-ol, 17-(cyclopropylmethyl)- (8CI,9CI); SCHEMBL159134; CTK4I5050; ZINC4215487; PDSP2_000668; BDBM50135800; N-cyclopropylmethyl 3-hydroxymorphinan; 3-Hydroxy-N-cyclopropylmethylmorphinan; LS-91818; (-)-17-(Cyclopropylmethyl)morphinan-3-ol; (-)-3-Hydroxy-N-cycloproypylmethylmorphinan Mandelate
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5359966
CAS Number
CAS 4163-15-9
TTD Drug ID
DMB1U8V

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Opioid receptor mu (MOP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Buprenorphine DMPRI8G Opioid dependence 6C43.2Z Approved [4]
Morphine DMRMS0L Advanced cancer 2A00-2F9Z Approved [5]
Hydromorphone DMHP21E Back pain ME84.Z Approved [6]
Tapentadol hydrochloride DMXLSH3 Acute pain MG31 Approved [7]
Fentanyl DM8WAHT Analgesia MB40.8 Approved [8]
Alfentanil DMVO0UB Anaesthesia 9A78.6 Approved [9]
Naloxegol DML0B41 Opioid-induced constipation DB32.1 Approved [10]
Eluxadoline DMYZ0P1 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [11]
Nalfurafine hcl DMA9DHW Uremic pruritus EC90.10 Approved [12]
Oxycodone DMXLKHV Osteoarthritis FA00-FA05 Approved [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Opioid receptor delta (OPRD1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Codeine DMJX6ZG Allergic rhinitis CA08.0 Approved [14]
Hydromorphone DMHP21E Back pain ME84.Z Approved [15]
Loperamide DMOJZQ9 Diarrhea ME05.1 Approved [16]
Eluxadoline DMYZ0P1 Diarrhea-predominant irritable bowel syndrome DD91.01 Approved [11]
Oxycodone DMXLKHV Osteoarthritis FA00-FA05 Approved [17]
Butorphanol DM5KYPJ Pain MG30-MG3Z Approved [14]
Carfentanil DM7ADGX N. A. N. A. Phase 2 [18]
Met-enkephalin DMSZFTP Pain MG30-MG3Z Phase 2 [19]
AZD-2327 DM8FZOG Anxiety disorder 6B00-6B0Z Phase 2 [20]
ADL-5747 DMMUPTN Pain MG30-MG3Z Phase 2 [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Opioid receptor kappa (OPRK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nalbuphine DMOSQGU Pain MG30-MG3Z Approved [22]
Nalfurafine hcl DMA9DHW Uremic pruritus EC90.10 Approved [12]
CHLOROXINE DMFZBMQ Erythema ME64.0 Approved [23]
Difelikefalin DMHZBEO Pruritus EC90 Approved [24]
Dezocine DMJDB0Y Pain MG30-MG3Z Approved [25]
Asimadoline DMND3AB Diarrhea-predominant irritable bowel syndrome DD91.01 Phase 3 [26]
JNJ 67953964 DMJ8Y5N Major depressive disorder 6A70.3 Phase 3 [27]
PHN-131 DM1SV8I Pain MG30-MG3Z Phase 2/3 [28]
CR-845 DMJYTUQ Pain MG30-MG3Z Phase 2/3 [29]
Carfentanil DM7ADGX N. A. N. A. Phase 2 [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Mu-type opioid receptor (OPRM1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alvimopan DMHR8KW Gastrointestinal disease DE2Z Approved [30]
Fentanyl DM8WAHT Analgesia MB40.8 Approved [31]
Morphine DMRMS0L Advanced cancer 2A00-2F9Z Approved [32]
Methotrexate DM2TEOL Anterior urethra cancer Approved [33]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [34]
Butorphanol DM5KYPJ Pain MG30-MG3Z Approved [35]
Oliceridine DM6MDCF Acute pain MG31 Approved [31]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [36]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [37]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Kappa-type opioid receptor (OPRK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [39]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [40]
Panobinostat DM58WKG Chronic graft versus host disease Approved [41]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [42]
Ethanol DMDRQZU Chronic pain MG30 Approved [43]
Folic Acid DMEMBJC Colorectal carcinoma Approved [44]
Morphine DMRMS0L Advanced cancer 2A00-2F9Z Approved [45]
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [41]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [46]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [47]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor delta (OPRD1) TT27RFC OPRD_HUMAN Inhibitor [2]
Opioid receptor kappa (OPRK1) TTQW87Y OPRK_HUMAN Inhibitor [1]
Opioid receptor mu (MOP) TTKWM86 OPRM_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Kappa-type opioid receptor (OPRK1) OTXCZF4L OPRK_HUMAN Protein Interaction/Cellular Processes [3]
Mu-type opioid receptor (OPRM1) OT16AAT8 OPRM_HUMAN Protein Interaction/Cellular Processes [3]

References

1 Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pha... J Med Chem. 2000 Jan 13;43(1):114-22.
2 Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
3 Aminothiazolomorphinans with mixed and opioid activity. J Med Chem. 2011 Mar 24;54(6):1903-13. doi: 10.1021/jm101542c. Epub 2011 Feb 25.
4 Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
5 Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
6 Clinical pipeline report, company report or official report of signaturerx.
7 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
8 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
9 Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
10 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
11 Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
12 Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
14 Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16.
15 Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12.
16 Loperamide: evidence of interaction with mu and delta opioid receptors. Life Sci. 1983;33 Suppl 1:315-8.
17 Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007 May;9(5):298-307.
18 Wax PM, Becker CE, Curry SC: Unexpected gas casualties in Moscow: a medical toxicology perspective. Ann Emerg Med. 2003 May;41(5):700-5.
19 Delta-opioid receptor agonists inhibit neuromuscular transmission in human colon. Eur J Pharmacol. 1994 Sep 1;262(1-2):33-9.
20 Preclinical pharmacology of AZD2327: a highly selective agonist of the delta-opioid receptor. J Pharmacol Exp Ther. 2011 Jul;338(1):195-204.
21 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 317).
22 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
23 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
24 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
25 Pharmacological profiles of opioid ligands at kappa opioid receptors. BMC Pharmacol. 2006 Jan 25;6:3.
26 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
27 Kappa Opioid Receptor Antagonists as Potential Therapeutics for Mood and Substance Use Disorders. Handb Exp Pharmacol. 2022;271:473-491.
28 Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic. J Pharmacol Exp Ther. 1988 Jan;244(1):391-402.
29 Peptide Kappa Opioid Receptor Ligands: Potential for Drug Development. AAPS J. 2009 June; 11(2): 312-322.
30 The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Naunyn Schmiedebergs Arch Pharmacol. 2007 May;375(3):205-20. doi: 10.1007/s00210-007-0146-x. Epub 2007 Mar 6.
31 A G protein-biased ligand at the ?-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013 Mar;344(3):708-17.
32 Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008 Apr;83(4):559-66.
33 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
34 The effect of mitragynine on cAMP formation and mRNA expression of mu-opioid receptors mediated by chronic morphine treatment in SK-N-SH neuroblastoma cell. J Ethnopharmacol. 2013 Jun 21;148(1):135-43. doi: 10.1016/j.jep.2013.03.078. Epub 2013 Apr 19.
35 In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances. Arch Toxicol. 2020 Nov;94(11):3819-3830. doi: 10.1007/s00204-020-02855-7. Epub 2020 Jul 31.
36 Cannabinoid receptor type 2 agonists induce transcription of the mu-opioid receptor gene in Jurkat T cells. Mol Pharmacol. 2006 Apr;69(4):1486-91. doi: 10.1124/mol.105.018325. Epub 2006 Jan 24.
37 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
38 Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-aza-2'-deoxycytidine. Neuroimmunomodulation. 2012;19(3):180-6. doi: 10.1159/000331474. Epub 2012 Jan 18.
39 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
40 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
41 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
42 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
43 The role of acetaldehyde in mediating effects of alcohol on expression of endogenous opioid system genes in a neuroblastoma cell line. FASEB J. 2008 Mar;22(3):662-70. doi: 10.1096/fj.07-8346com. Epub 2007 Oct 12.
44 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
45 In vivo and in vitro evaluation of novel -opioid receptor agonist compounds. Eur J Pharmacol. 2015 Nov 15;767:193-200. doi: 10.1016/j.ejphar.2015.10.025. Epub 2015 Oct 20.
46 Effects of tobacco compounds on gene expression in fetal lung fibroblasts. Environ Toxicol. 2008 Aug;23(4):423-34.
47 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.